Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
[Prevention of multiple sclerosis: A realistic goal?]
Development and assessment of a website presenting evidence-based information for people with multiple sclerosis: the IN-DEEP project.
Humoral mechanisms in T cell vaccination: induction and functional characterization of anti-lymphocytic autoantibodies.
Natalizumab discontinuation and disease restart in pregnancy: a case series.
Natalizumab restores aberrant miRNA expression profile in multiple sclerosis and reveals a critical role for miR-20b.
Purkinje cell pathology and loss in multiple sclerosis cerebellum.
T cell vaccination benefits relapsing progressive multiple sclerosis patients: a randomized, double-blind clinical trial.
Total-tau in cerebrospinal fluid of patients with multiple sclerosis decreases in secondary progressive stage of disease and reflects degree of brain atrophy.
Quality of Life Assessment in Patients with Multiple Sclerosis Receiving Interferon Beta-1a: A Comparative Longitudinal Study of Avonex and Its Biosimilar CinnoVex.
Integrin/Chemokine Receptor Interactions in the Pathogenesis of Experimental Autoimmune Encephalomyelitis.
Glycoengineering of Interferon-β 1a Improves Its Biophysical and Pharmacokinetic Properties.
Gray matter involvement in multiple sclerosis.
Riluzole specifically blocks inactivated Na channels in myelinated nerve fibre.
Regulation of Neuroinflammation through Programed Death-1/Programed Death Ligand Signaling in Neurological Disorders.
Cannabinoids in the management of difficult to treat pain.
Increased promoter methylation of the immune regulatory gene SHP-1 in leukocytes of multiple sclerosis subjects.
Value of NMO-IgG determination at the time of presentation as CIS.
Acute reversible periependymal ventricular enhancement in neuromyelitis optica.
[Damage of macular ganglion cell complex and peripapillary retinal nerve fiber layer in multiple sclerosis.]
Increased risk of multiple sclerosis relapse after in vitro fertilisation.
Pathogenic and regulatory roles for B cells in experimental autoimmune encephalomyelitis.
Deletion of IL-4Rα in the BALB/c mouse is associated with altered lesion topography and susceptibility to experimental autoimmune encephalomyelitis.
Decreased urinary level of melatonin as a marker of disease severity in patients with multiple sclerosis.
Ibuprofen-induced unilateral optic neuritis.
Adult mesenchymal stem cell therapy for myelin repair in Multiple Sclerosis.
Pages
« first
‹ previous
…
209
210
211
212
213
214
215
216
217
…
next ›
last »